ECSP10010612A - Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c - Google Patents

Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c

Info

Publication number
ECSP10010612A
ECSP10010612A EC2010010612A ECSP10010612A ECSP10010612A EC SP10010612 A ECSP10010612 A EC SP10010612A EC 2010010612 A EC2010010612 A EC 2010010612A EC SP10010612 A ECSP10010612 A EC SP10010612A EC SP10010612 A ECSP10010612 A EC SP10010612A
Authority
EC
Ecuador
Prior art keywords
hepatitis
macrociclic
inhibitors
new
virus replication
Prior art date
Application number
EC2010010612A
Other languages
English (en)
Inventor
Brad Buckman
Scott D Seiwert
Leonid Beigelman
Antitsa Dimitrova Stoycheva
Steven B Porter
Williamson Ziegler Bradford
Vladimir Serebryany
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of ECSP10010612A publication Critical patent/ECSP10010612A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/123—Tripeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compuestos de las formulas generales I, II, III, IV, V, VI, VII y X, y composiciones, incluyendo composiciones farmaceuticas, que comprenden dichos compuestos. Ademas, las realizaciones proveen metodos de tratamiento, incluyendo metodos para tratar una infeccion de virus de hepatitis C y metodos para tratar la fibrosis hepatica, donde los metodos generalmente comprenden administrarle a un individuo que lo necesita una cantidad eficaz de uno de los compuestos o las composiciones de la invencion.
EC2010010612A 2008-04-15 2010-11-15 Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c ECSP10010612A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4522008P 2008-04-15 2008-04-15
US10573608P 2008-10-15 2008-10-15
US10575108P 2008-10-15 2008-10-15
US14372809P 2009-01-09 2009-01-09
US15069309P 2009-02-06 2009-02-06

Publications (1)

Publication Number Publication Date
ECSP10010612A true ECSP10010612A (es) 2010-12-30

Family

ID=41215217

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010612A ECSP10010612A (es) 2008-04-15 2010-11-15 Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c

Country Status (22)

Country Link
US (2) US8048862B2 (es)
EP (1) EP2282762A2 (es)
JP (1) JP2011519364A (es)
KR (1) KR20110005869A (es)
CN (1) CN102046622A (es)
AP (1) AP2010005416A0 (es)
AR (1) AR072779A1 (es)
AU (1) AU2009249443A1 (es)
BR (1) BRPI0911260A2 (es)
CA (1) CA2720729A1 (es)
CO (1) CO6321290A2 (es)
CU (1) CU20100203A7 (es)
EA (1) EA201071034A1 (es)
EC (1) ECSP10010612A (es)
IL (1) IL208529A0 (es)
MA (1) MA32225B1 (es)
MX (1) MX2010011306A (es)
NI (1) NI201000174A (es)
SG (1) SG175692A1 (es)
TW (1) TW200948376A (es)
WO (1) WO2009142842A2 (es)
ZA (1) ZA201007256B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003007697A (ja) * 2001-06-21 2003-01-10 Hitachi Kokusai Electric Inc 半導体装置の製造方法、基板処理方法および基板処理装置
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
JP5249028B2 (ja) 2005-07-25 2013-07-31 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
GEP20104956B (en) * 2005-10-11 2010-04-12 Array Biopharma Inc Compounds for inhibiting hepatitis c viral replication and use thereof
KR20100024920A (ko) * 2007-05-03 2010-03-08 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 마크로사이클릭 저해제
MX2009012093A (es) 2007-05-10 2010-01-25 Intermune Inc Nuevos peptidos inhibidores de la replicacion del virus de la hepatitis c.
KR20110005869A (ko) 2008-04-15 2011-01-19 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규한 마크로사이클릭 억제제
US20090285773A1 (en) * 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
CN102216321A (zh) * 2008-10-15 2011-10-12 因特蒙公司 治疗性抗病毒肽
JP2012516351A (ja) * 2009-01-30 2012-07-19 アナコール ファーマシューティカルズ，インコーポレーテッド 化合物
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
US20110129444A1 (en) * 2009-09-28 2011-06-02 Intermune, Inc Novel macrocyclic inhibitors of hepatitis c virus replication
WO2011038293A1 (en) * 2009-09-28 2011-03-31 Intermune, Inc. Cyclic peptide inhibitors of hepatitis c virus replication
WO2011041551A1 (en) * 2009-10-01 2011-04-07 Intermune, Inc. Therapeutic antiviral peptides
KR101781789B1 (ko) * 2010-01-27 2017-09-26 에이비 파르마 리미티드. C형 간염 바이러스 억제제로 사용되는 다환 헤테로사이클릭 화합물
JP5717768B2 (ja) * 2010-03-10 2015-05-13 アッヴィ・バハマズ・リミテッド 固体組成物
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
WO2012054874A1 (en) * 2010-10-22 2012-04-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
EP2635570B1 (en) 2010-11-01 2017-12-13 RFS Pharma, LLC. Novel specific hcv ns3 protease inhibitors
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
WO2012092411A2 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc. Phenanthridine macrocyclic hepatitis c serine protease inhibitors
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012171332A1 (zh) 2011-06-16 2012-12-20 爱博新药研发(上海)有限公司 抑制丙型肝炎病毒的大环状杂环化合物及其制备和应用
SI2709613T2 (sl) 2011-09-16 2020-12-31 Gilead Pharmasset LLC c/o Gilead Sciences, Inc. Postopki za zdravljenje HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
CA2863002A1 (en) 2012-01-11 2013-07-18 Abbvie Inc. Processes for making hcv protease inhibitors
CN104039774A (zh) 2012-01-12 2014-09-10 Rfs制药公司 Hcv ns3蛋白酶抑制剂
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
EP2903988A1 (en) 2012-10-08 2015-08-12 AbbVie Inc. Compounds useful for making hcv protease inhibitors
SI2909205T1 (sl) 2012-10-19 2017-02-28 Bristol-Myers Squibb Company 9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
NZ729172A (en) 2013-01-31 2018-06-29 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SG11201507223TA (en) 2013-03-15 2015-10-29 Gilead Sciences Inc Macrocyclic and bicyclic inhibitors of hepatitis c virus
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN104311544A (zh) * 2014-09-22 2015-01-28 湖南华腾制药有限公司 一种苯并恶唑衍生物的制备方法
CN104327061A (zh) * 2014-10-19 2015-02-04 湖南华腾制药有限公司 一种溴苯并[d]恶唑衍生物的制备方法
CN104292179A (zh) * 2014-10-19 2015-01-21 湖南华腾制药有限公司 一种2-氯苯并[d]恶唑-5-甲醛的制备方法
WO2016127859A1 (en) * 2015-02-13 2016-08-18 Sunshine Lake Pharma Co., Ltd. Compounds as hepatitis c inhibitors and uses thereof in medicine
MA41812A (fr) 2015-03-27 2018-01-30 Janssen Pharmaceuticals Inc Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc
CN105503851B (zh) * 2015-12-09 2017-06-23 重庆润生科技有限公司 一种烯基噻唑衍生物的制备方法
CN109616152B (zh) * 2018-12-06 2020-01-03 中国人民解放军军事科学院军事医学研究院 癌症特异的共调网络建立方法及装置

Family Cites Families (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798209A (en) * 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
CS263951B1 (en) * 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
NZ216172A (en) 1985-05-15 1989-08-29 Wellcome Found Nucleosides and pharmaceutical compositions
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
US5232928A (en) 1989-07-25 1993-08-03 Boehringer Ingelheim Pharmaceuticals, Inc. Tetrahydroisoquinoline amides
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6693072B2 (en) * 1994-06-02 2004-02-17 Aventis Pharmaceuticals Inc. Elastase inhibitors
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US7157430B2 (en) 1998-10-22 2007-01-02 Idun Pharmaceuticals, Inc. (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
JP4806154B2 (ja) 2000-04-03 2011-11-02 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼのインヒビター
JP4748911B2 (ja) * 2000-04-05 2011-08-17 シェーリング コーポレイション Ｎ−環状ｐ２部分を含むｃ型肝炎ウイルスの大環状ｎｓ３‐セリンプロテアーゼ阻害剤
NZ521456A (en) * 2000-04-19 2004-07-30 Schering Corp Macrocyclic NS3-Serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
MXPA03000627A (es) * 2000-07-21 2004-07-30 Schering Corp Nuevos peptidos como inhibidores de proteasa serina-ns3 del virus de la hepatitis c.
CA2429359A1 (en) 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
DE60229059D1 (de) 2001-05-08 2008-11-06 Univ Yale Proteomimetische verbindungen und verfahren
CA2449504A1 (en) * 2001-07-11 2003-01-23 Vertex Pharmaceuticals Incorporated Bridged bicyclic serine protease inhibitors
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
CA2370400A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
JP2005535574A (ja) * 2002-04-11 2005-11-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特にｈｃｖｎｓ３−ｎｓ４ａプロテアーゼのインヒビター
AU2003231765B9 (en) * 2002-04-26 2010-01-28 Gilead Sciences, Inc. Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds and the compounds as such
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US6878722B2 (en) * 2002-05-20 2005-04-12 Bristol-Myers Squibb Company Substituted cycloalkyl P1′ hepatitis C virus inhibitors
EP1506000B9 (en) * 2002-05-20 2011-08-31 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
WO2004032827A2 (en) * 2002-05-20 2004-04-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US20040138109A1 (en) 2002-09-30 2004-07-15 Boehringer Ingelheim Pharmaceuticals, Inc. Potent inhibitor of HCV serine protease
DE10246957A1 (de) * 2002-10-09 2004-04-22 Bayer Ag Polycarbonat enthaltend Diphenylcarbonat und Platten enthaltend dieses Polycarbonat
PL199412B1 (pl) 2002-10-15 2008-09-30 Boehringer Ingelheim Int Nowe kompleksy rutenu jako (pre)katalizatory reakcji metatezy, pochodne 2-alkoksy-5-nitrostyrenu jako związki pośrednie i sposób ich wytwarzania
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
US20040180815A1 (en) 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
EP1601685A1 (en) 2003-03-05 2005-12-07 Boehringer Ingelheim International GmbH Hepatitis c inhibiting compounds
UY28240A1 (es) 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
UA81028C2 (en) * 2003-04-02 2007-11-26 Boehringer Ingelheim Int Pharmaceutical compositions for hepatitis c viral protease inhibitors
JP4231524B2 (ja) * 2003-04-10 2009-03-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大環状化合物の製造方法
TW200510391A (en) * 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
EP1629000B1 (en) * 2003-04-16 2009-02-18 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
US7176208B2 (en) * 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
PL1628685T3 (pl) 2003-04-25 2011-05-31 Gilead Sciences Inc Przeciwwirusowe analogi fosfonianowe
US7300924B2 (en) 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
US20040229848A1 (en) 2003-05-05 2004-11-18 Hans-Ulrich Demuth Glutaminyl based DP IV-inhibitors
US7273851B2 (en) 2003-06-05 2007-09-25 Enanta Pharmaceuticals, Inc. Tri-peptide hepatitis C serine protease inhibitors
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
CA2538791A1 (en) * 2003-09-18 2005-03-31 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
KR20060085248A (ko) * 2003-09-26 2006-07-26 쉐링 코포레이션 Ｃ형 간염 바이러스 ｎｓ3 세린 프로테아제의마크로사이클릭 억제제
CA2541634A1 (en) * 2003-10-10 2005-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
TW201245229A (en) * 2003-10-14 2012-11-16 Hoffmann La Roche Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
JP4890254B2 (ja) * 2003-10-27 2012-03-07 バーテックス ファーマシューティカルズ インコーポレイテッド Ｈｃｖｎｓ３−ｎｓ４ａプロテアーゼ耐性突然変異体
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2005053735A1 (en) * 2003-11-20 2005-06-16 Boehringer Ingelheim International Gmbh Method of removing transition metals, especially from metathesis reaction products
US7309708B2 (en) * 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
JP2007532479A (ja) * 2003-11-20 2007-11-15 シェーリング　コーポレイション Ｃ型肝炎ウイルスｎｓ３プロテアーゼの脱ペプチド化インヒビター
CA2549167A1 (en) 2003-12-11 2005-06-30 Schering Corporation Inhibitors of hepatitis c virus ns3/ns4a serine protease
ATE495185T1 (de) 2004-01-21 2011-01-15 Boehringer Ingelheim Int Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
KR20120090077A (ko) 2004-01-30 2012-08-16 얀센 알 앤드 디 아일랜드 Ｈｃｖ ｎｓ?３ 세린 프로테아제 저해제
EP2311851A3 (en) 2004-02-04 2011-05-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
ES2328589T3 (es) 2004-02-27 2009-11-16 Schering Corporation Compuestos de la prolina 3,4(ciclopentil) fusionados como inhibidores de la proteasa serina ns3 del virus de la hepatitis c.
US7205330B2 (en) 2004-02-27 2007-04-17 Schering Corporation Inhibitors of hepatitis C virus NS3 protease
US7816326B2 (en) 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
AU2005219824B2 (en) * 2004-02-27 2007-11-29 Merck Sharp & Dohme Corp. Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus
DE602005023224D1 (de) 2004-02-27 2010-10-07 Schering Corp Neuartige Verbindungen als Hemmer von Hepatitis C-Virus NS3-Serinprotease
JP4654239B2 (ja) 2004-03-15 2011-03-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウィルス感染症の治療に適した大環状ジペプチドの調製方法
CN1984922A (zh) 2004-05-20 2007-06-20 先灵公司 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的取代脯氨酸
WO2005116054A1 (en) 2004-05-25 2005-12-08 Boehringer Ingelheim International, Gmbh Process for preparing acyclic hcv protease inhibitors
US7939538B2 (en) * 2004-06-28 2011-05-10 Amgen Inc. Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
US20060069316A1 (en) * 2004-07-02 2006-03-30 Discus Dental Impressions, Inc. Retracting devices
DE102004033312A1 (de) * 2004-07-08 2006-01-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren
DK1778702T3 (da) * 2004-07-16 2011-10-17 Gilead Sciences Inc Antivirale forbindelser
JP4914355B2 (ja) * 2004-07-20 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類似体
CA2577812A1 (en) * 2004-08-27 2006-03-09 Schering Corporation Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease
US7189844B2 (en) * 2004-09-17 2007-03-13 Boehringer Ingelheim International Gmbh Ring-closing metathesis process in supercritical fluid
EP1794178A1 (en) 2004-09-17 2007-06-13 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic hcv protease inhibitors
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7524831B2 (en) 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
EP1863941B1 (en) 2005-03-04 2013-05-08 The Rockefeller University Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
NZ562167A (en) 2005-03-08 2011-01-28 Boehringer Ingelheim Int Process for preparing macrocyclic compounds
WO2006119061A2 (en) * 2005-05-02 2006-11-09 Merck & Co., Inc. Hcv ns3 protease inhibitors
MX2007014889A (es) 2005-05-26 2008-02-19 Schering Corp Fusion de interferon-inmunoglobulina g.
WO2006130627A2 (en) 2005-06-02 2006-12-07 Schering Corporation Methods for treating hepatitis c
US20060275366A1 (en) 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
US7608592B2 (en) * 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
US7601686B2 (en) * 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW200738742A (en) * 2005-07-14 2007-10-16 Gilead Sciences Inc Antiviral compounds
TWI389908B (zh) * 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
TWI387603B (zh) * 2005-07-20 2013-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
JP5249028B2 (ja) 2005-07-25 2013-07-31 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
ES2373685T3 (es) * 2005-07-29 2012-02-07 Tibotec Pharmaceuticals Inhibidores macrocíclicos del virus de la hepatitis c.
GEP20104956B (en) * 2005-10-11 2010-04-12 Array Biopharma Inc Compounds for inhibiting hepatitis c viral replication and use thereof
US7772183B2 (en) * 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) * 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
EP1951717A1 (en) * 2005-11-16 2008-08-06 F.Hoffmann-La Roche Ag Novel pyrrolidine derivatives as inhibitors of coagulation factor xa
WO2007109080A2 (en) * 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
US7728148B2 (en) * 2006-06-06 2010-06-01 Enanta Pharmaceuticals, Inc. Acyclic oximyl hepatitis C protease inhibitors
US9526769B2 (en) 2006-06-06 2016-12-27 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
EP2029741A4 (en) 2006-06-08 2011-03-16 Merck Sharp & Dohme QUICK PROCEDURE FOR DETERMINING THE HEMMERSENSITIVITY OF NS3 / 4A PROTEASE SEQUENCES CLONED FROM CLINICAL SAMPLES
UY30437A1 (es) 2006-06-26 2008-01-31 Enanta Pharm Inc Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
US20090227491A1 (en) * 2006-07-07 2009-09-10 Gilead Sciences, Inc. Antiviral phosphinate compounds
EP2049474B1 (en) * 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CA2657618C (en) * 2006-07-13 2016-10-11 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
CN101674844A (zh) * 2006-08-04 2010-03-17 英安塔制药有限公司 四唑基大环类c型肝炎丝氨酸蛋白酶抑制剂
US7635683B2 (en) * 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
US20090035267A1 (en) * 2007-07-31 2009-02-05 Moore Joel D Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
US7718612B2 (en) * 2007-08-02 2010-05-18 Enanta Pharmaceuticals, Inc. Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
US20080038225A1 (en) * 2006-08-11 2008-02-14 Ying Sun Triazolyl acyclic hepatitis c serine protease inhibitors
US20090098085A1 (en) * 2006-08-11 2009-04-16 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
US7662779B2 (en) * 2006-08-11 2010-02-16 Enanta Pharmaceuticals, Inc. Triazolyl macrocyclic hepatitis C serine protease inhibitors
US20090035268A1 (en) * 2007-08-01 2009-02-05 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
US7605126B2 (en) * 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors
US7687459B2 (en) * 2006-08-11 2010-03-30 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis C virus protease inhibitors
US8343477B2 (en) * 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US20080107625A1 (en) * 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US7772180B2 (en) * 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2661338C (en) * 2006-11-17 2015-05-12 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
EP2125870A4 (en) * 2007-02-16 2011-04-06 Boehringer Ingelheim Int INHIBITORS OF HEPATITIS C NS3 PROTEASE
JP2010522172A (ja) * 2007-03-23 2010-07-01 シェーリング コーポレイション Ｈｃｖｎｓ３プロテアーゼのｐ１−非エピメリ化ケトアミド阻害剤
AU2008240834B2 (en) 2007-04-24 2012-08-23 F. Hoffmann-La Roche Ag Process for HCV protease inhibitor intermediate
WO2008134395A1 (en) 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis c serine protease inhibitors
US7906513B2 (en) 2007-04-26 2011-03-15 Enanta Pharmaceuticals, Inc. Hydrazide-containing hepatitis C serine protease inhibitors
US20080267917A1 (en) 2007-04-26 2008-10-30 Deqiang Niu N-functionalized amides as hepatitis c serine protease inhibitors
US20090123423A1 (en) * 2007-04-26 2009-05-14 Yonghua Gai Hydroxyamic analogs as hepatitis c virus serine protease inhibitor
US20080274082A1 (en) 2007-04-26 2008-11-06 Yonghua Gai Oximyl hydroxyamic analogs as hepatitis c virus protease inhibitor
US8377872B2 (en) 2007-04-26 2013-02-19 Enanta Pharmaceuticals, Inc. Cyclic P3 tripeptide hepatitis C serine protease inhibitors
US20080279821A1 (en) 2007-04-26 2008-11-13 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors
US20080317712A1 (en) 2007-04-26 2008-12-25 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl tripeptide hepatitis c serine protease inhibitors
US7910587B2 (en) 2007-04-26 2011-03-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl dipeptide hepatitis C virus inhibitors
KR20100024920A (ko) * 2007-05-03 2010-03-08 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 마크로사이클릭 저해제
MX2009012093A (es) 2007-05-10 2010-01-25 Intermune Inc Nuevos peptidos inhibidores de la replicacion del virus de la hepatitis c.
US20090005387A1 (en) * 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
WO2009014730A1 (en) * 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US20090053175A1 (en) * 2007-08-24 2009-02-26 Yat Sun Or Substitute pyrrolidine derivatives
US20090060874A1 (en) * 2007-09-05 2009-03-05 Yao-Ling Qiu Bicyclic pyrrolidine derivatives
EP2190858A4 (en) * 2007-09-24 2013-02-13 Achillion Pharmaceuticals Inc PEPTIDES CONTAINING UREA AS INHIBITORS OF VIRAL REPLICATION
US20090082366A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched telaprevir
WO2009055335A2 (en) * 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
US8383583B2 (en) * 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
US8426360B2 (en) * 2007-11-13 2013-04-23 Enanta Pharmaceuticals, Inc. Carbocyclic oxime hepatitis C virus serine protease inhibitors
US8030307B2 (en) 2007-11-29 2011-10-04 Enanta Pharmaceuticals, Inc. Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease
US8361958B2 (en) 2007-12-05 2013-01-29 Enanta Pharmaceuticals, Inc. Oximyl HCV serine protease inhibitors
US8283309B2 (en) 2007-12-20 2012-10-09 Enanta Pharmaceuticals, Inc. Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors
JP5439384B2 (ja) 2007-12-21 2014-03-12 エフ．ホフマン−ラ ロシュ アーゲー 大員環の製造方法
KR20100118991A (ko) 2008-02-04 2010-11-08 아이데닉스 파마슈티칼스, 인코포레이티드 매크로시클릭 세린 프로테아제 억제제
MX2010008371A (es) 2008-02-07 2010-10-04 Virobay Inc Inhibidores de catepsina b.
ES2388994T3 (es) 2008-04-11 2012-10-22 F. Hoffmann-La Roche Ag Nuevos complejos de rutenio, como catalizadores para reacciones de metátesis
KR20110005869A (ko) * 2008-04-15 2011-01-19 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규한 마크로사이클릭 억제제
WO2009134987A1 (en) 2008-04-30 2009-11-05 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis c virus inhibitors
US20090285773A1 (en) 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20090285774A1 (en) 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN101580535B (zh) 2008-05-16 2012-10-03 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂
US8044023B2 (en) 2008-05-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010014134A1 (en) * 2008-07-02 2010-02-04 Idenix Pharamaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US7906655B2 (en) * 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8603737B2 (en) * 2008-09-19 2013-12-10 Celgene Avilomics Research, Inc. Methods for identifying HCV protease inhibitors
US20100080770A1 (en) * 2008-09-29 2010-04-01 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8563505B2 (en) * 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) * 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102216321A (zh) * 2008-10-15 2011-10-12 因特蒙公司 治疗性抗病毒肽
US8445430B2 (en) * 2008-11-20 2013-05-21 Achillion Pharmaceuticals, Inc. Cyclic carboxamide compounds and analogues thereof as of hepatitis C virus
NZ592705A (en) 2008-12-10 2013-02-22 Achillion Pharmaceuticals Inc 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201034663A (en) 2008-12-19 2010-10-01 Gilead Sciences Inc HCV NS3 protease inhibitors
AR074758A1 (es) 2008-12-22 2011-02-09 Gilead Sciences Inc Compuestos macrociclicos antivirales
JP2012516351A (ja) 2009-01-30 2012-07-19 アナコール ファーマシューティカルズ，インコーポレーテッド 化合物
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
WO2011038293A1 (en) * 2009-09-28 2011-03-31 Intermune, Inc. Cyclic peptide inhibitors of hepatitis c virus replication
US20110129444A1 (en) * 2009-09-28 2011-06-02 Intermune, Inc Novel macrocyclic inhibitors of hepatitis c virus replication
WO2011041551A1 (en) * 2009-10-01 2011-04-07 Intermune, Inc. Therapeutic antiviral peptides

Also Published As

Publication number Publication date
AP2010005416A0 (en) 2010-10-31
AU2009249443A1 (en) 2009-11-26
US8048862B2 (en) 2011-11-01
WO2009142842A3 (en) 2010-04-01
EA201071034A1 (ru) 2011-06-30
MA32225B1 (fr) 2011-04-01
CA2720729A1 (en) 2009-11-26
CN102046622A (zh) 2011-05-04
IL208529A0 (en) 2010-12-30
ZA201007256B (en) 2013-03-27
US20090269305A1 (en) 2009-10-29
NI201000174A (es) 2011-08-24
CO6321290A2 (es) 2011-09-20
TW200948376A (en) 2009-12-01
BRPI0911260A2 (pt) 2015-09-29
WO2009142842A2 (en) 2009-11-26
AR072779A1 (es) 2010-09-22
US20110059047A1 (en) 2011-03-10
CU20100203A7 (es) 2012-06-21
JP2011519364A (ja) 2011-07-07
EP2282762A2 (en) 2011-02-16
MX2010011306A (es) 2010-11-09
KR20110005869A (ko) 2011-01-19
SG175692A1 (en) 2011-11-28
WO2009142842A9 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
CO6321290A2 (es) Nuevos inhibidores macrociclicos basados en pirrolidinilo de la replicacion de virus de la hepatitis c
ECSP099780A (es) Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c
NI200900205A (es) Nuevos péptidos inhibidores de la replicación del virus de la hepatitis c.
AR055095A1 (es) Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c
CU20090209A7 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
ECSP066570A (es) Ácidos carboxílicos macrocíclicos y acilsulfonamidas como inhibidores de replicación del hcv
CU20090112A6 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
CL2012001960A1 (es) Compuestos derivados de ácido tiofeno-2-carboxílico; inhibidores de virus flaviviridae; composición farmacéutica que los comprende; utiles en el tratamiento de la hepatitis c. pct fase nacional
MX2012003171A (es) Novedosos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
WO2012087976A3 (en) Novel inhibitors of hepatitis c virus replication
UY32793A (es) Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos
CL2013003360A1 (es) “compuestos derivados de 4-aril-n-[3-(sulfonimidoil)fenil]-1,3,5-triazin-2-amina sustituidos, inhibidores cdk; compuestos intermediarios, composición y combinación farmacéutica que los comprende; y su uso en el tratamiento de enfermedades hiperproliferativas, infecciosas inducidas por virus y/o cardiovasculares”. pct
TN2012000135A1 (en) Cyclic peptide inhibitors of hepatitis c virus replication
WO2007047146A3 (en) Inhibitors of viral replication
CR11499A (es) Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c
DOP2014000133A (es) Triazolopiridinas sustituidas
MX387352B (es) Nuevos inhibidores de replicación viral.
CL2011000558A1 (es) Formas cristalinas de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; sal de sodio del compuesto, composicion farmaceutica que comprende la sal de sodio, util para tratar una infeccion por el virus de la hepatitis c.
WO2009134616A8 (en) Novel inhibitors of hepatitis c virus replication
CU20090182A7 (es) Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c
NI200700218A (es) Derivados de amida como ligandos de canales iónicos y composiciones farmacéuticas y métodos para usar los mismos.
CU20090188A7 (es) Nuevos péptidos inhibidores de la replicación del virus de la hepatitis c
CU23602A3 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
TN2010000468A1 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
UA95455C2 (ru) Макроциклические ингибиторы репликации вируса гепатита с